{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T15:16:00Z","timestamp":1769526960219,"version":"3.49.0"},"update-to":[{"DOI":"10.1002\/14651858.cd003626","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2011,1,19]],"date-time":"2011-01-19T00:00:00Z","timestamp":1295395200000}}],"reference-count":93,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd003626.pub2","type":"journal-article","created":{"date-parts":[[2011,1,6]],"date-time":"2011-01-06T00:39:55Z","timestamp":1294274395000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Bile acids for primary sclerosing cholangitis"],"prefix":"10.1002","volume":"2011","author":[{"given":"Goran","family":"Poropat","sequence":"first","affiliation":[{"name":"Clinical Hospital Centre Rijeka; Department of Gastroenterology; Kresimirova 42 Rijeka Croatia 51000"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanja","family":"Giljaca","sequence":"additional","affiliation":[{"name":"Clinical Hospital Centre Rijeka; Department of Gastroenterology; Kresimirova 42 Rijeka Croatia 51000"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davor","family":"Stimac","sequence":"additional","affiliation":[{"name":"Clinical Hospital Centre Rijeka; Department of Gastroenterology; Kresimirova 42 Rijeka Croatia 51000"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Gluud","sequence":"additional","affiliation":[{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 3344, Rigshospitalet, Copenhagen University Hospital; Cochrane Hepato-Biliary Group; Blegdamsvej 9 Copenhagen Denmark DK-2100"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,1,19]]},"reference":[{"issue":"4 pt 2","key":"10.1002\/14651858.CD003626.pub2-BIB0001|cit1","first-page":"64A","article-title":"Effect of ursodeoxycholic acid in primary sclerosing cholangitis: a controlled trial","volume":"14","author":"Beuers","year":"1991","journal-title":"Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD003626.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/hep.1840160315","article-title":"Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial","volume":"16","author":"Beuers","year":"1992","journal-title":"Hepatology"},{"issue":"12","key":"10.1002\/14651858.CD003626.pub2-BIB0003|cit3","first-page":"1472","article-title":"Ursodeoxycholic acid does not improve the clinical course of primary sclerosing cholangitis over a 2-year period","volume":"43","author":"Maria","year":"1996","journal-title":"Hepato-Gastroenterology"},{"issue":"10","key":"10.1002\/14651858.CD003626.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1056\/NEJM199703063361003","article-title":"Ursodiol for primary sclerosing cholangitis","volume":"336","author":"Lindor","year":"1997","journal-title":"The New England Journal of Medicine"},{"issue":"4 (Suppl)","key":"10.1002\/14651858.CD003626.pub2-BIB0005|cit5","first-page":"378A","article-title":"Randomized, double-blind controlled trial of high-dose ursodeoxycholic acid (UDCA) for primary sclerosing cholangitis (PSC)","volume":"48","author":"Lindor","year":"2008","journal-title":"Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD003626.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/hep.23082","article-title":"High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatology"},{"issue":"2 Pt 2","key":"10.1002\/14651858.CD003626.pub2-BIB0007|cit7","first-page":"92A","article-title":"Ursodeoxycholic acid in primary sclerosing cholangitis: a double-blind placebo controlled trial [AASLD abstract]","volume":"16","author":"Lo","year":"1992","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD003626.pub2-BIB0008|cit8","first-page":"1146A","article-title":"High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind, placebo-controlled trial","volume":"110","author":"Bansi","year":"1996","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003626.pub2-BIB0009|cit9","first-page":"A29","article-title":"High-dose ursodeoxycholic acid (UDCA) in primary sclerosing cholangitis (PSC): results after two years of a randomised double-blind, placebo-controlled trial","volume":"40","author":"Mitchell","year":"1997","journal-title":"Gut"},{"issue":"4","key":"10.1002\/14651858.CD003626.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1053\/gast.2001.27965","article-title":"A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis","volume":"121","author":"Mitchell","year":"2001","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD003626.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1053\/j.gastro.2005.08.017","article-title":"High-dose ursodeoxycholic acid in primary sclerosing cholangitis: A 5-year multicenter, randomized, controlled study","volume":"129","author":"Olsson","year":"2005","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD003626.pub2-BIB0012|cit12","first-page":"602","article-title":"Treatment of primary sclerosing cholangitis with ursodeoxycholic acid: first results of a controlled study","volume":"10","author":"Stiehl","year":"1989","journal-title":"Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD003626.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0168-8278(05)80467-2","article-title":"Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period","volume":"20","author":"Stiehl","year":"1994","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD003626.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/hep.21960","article-title":"Impact of inflammatory bowel disease and ursodeoxycholic acid therapy on small-duct primary sclerosing cholangitis","volume":"47","author":"Charatcharoenwitthaya","year":"2008","journal-title":"Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD003626.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/0168-8278(90)90281-U","article-title":"Ursodeoxycholic acid for primary sclerosing cholangitis","volume":"11","author":"Chazouilleres","year":"1990","journal-title":"Journal of Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003626.pub2-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"S234","DOI":"10.1016\/S0168-8278(06)80632-X","article-title":"Four-year outcome of primary sclerosing cholangitis (PSC) under low-dose ursodeoxycholic acid (UDCA): a French prospective study","volume":"44","author":"Garioud","year":"2006","journal-title":"Journal of Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD003626.pub2-BIB0017|cit17","first-page":"136","article-title":"Efficacy of ursodeoxycholic acid in the treatment of primary sclerosing cholangitis in children","volume":"31","author":"Gilger","year":"2000","journal-title":"Journal of Pediatric Gastroenterology and Nutrition"},{"issue":"5","key":"10.1002\/14651858.CD003626.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1111\/j.1572-0241.2001.03777.x","article-title":"High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis","volume":"96","author":"Harnois","year":"2001","journal-title":"American Journal of Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD003626.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/hep.1840140516","article-title":"Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study","volume":"14","author":"O'Brien","year":"1991","journal-title":"Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD003626.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S1590-8658(03)00076-8","article-title":"Treatment of primary sclerosing cholangitis with low-dose ursodeoxycholic acid: results of a retrospective Italian multicentre survey","volume":"35","author":"Okolicsanyi","year":"2003","journal-title":"Digestive and Liver Disease"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003626.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.1016\/0168-8278(91)91632-Q","article-title":"The effect of ursodeoxycholic acid on survival in patients with primary sclerosing cholangitis [EASL abstract]","volume":"13","author":"Rudolph","year":"1991","journal-title":"Journal of Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD003626.pub2-BIB0022|cit22","first-page":"123","article-title":"Primary sclerosing cholangitis: conventional and quantitative liver function tests during long-term therapy with ursodeoxycholic acid","volume":"34","author":"Schonfeld","year":"1996","journal-title":"Zeitschrift fur Gastroenterologie"},{"issue":"6","key":"10.1002\/14651858.CD003626.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0168-8278(96)80293-5","article-title":"Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response","volume":"25","author":"Meeberg","year":"1996","journal-title":"Journal of Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD003626.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0168-8278(98)80059-7","article-title":"Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses","volume":"29","author":"Hoogstraten","year":"1998","journal-title":"Journal of Hepatology"},{"issue":"8","key":"10.1002\/14651858.CD003626.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1111\/j.1572-0241.2000.02267.x","article-title":"Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian-Dutch PSC Study Group","volume":"95","author":"Hoogstraten","year":"2000","journal-title":"American Journal of Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD003626.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/00042737-199902000-00013","article-title":"Does ursodeoxycholic acid mediate immunomodulatory and anti-inflammatory effects in patients with primary sclerosing cholangitis?","volume":"11","author":"Milligen de Wit","year":"1999","journal-title":"European Journal of Gastroenterology and Hepatology"},{"issue":"2 Pt 2","key":"10.1002\/14651858.CD003626.pub2-BIB0027|cit27","first-page":"62A","article-title":"Ursodeoxycholic acid (UDCA) therapy for primary sclerosing cholangitis (PSC): preliminary report of a randomised controlled trial [AASLD abstract]","volume":"16","author":"Thiel","year":"1992","journal-title":"Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD003626.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/hep.510300101","article-title":"Primary sclerosing cholangitis","volume":"30","author":"Angulo","year":"1999","journal-title":"Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD003626.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1172\/JCI116921","article-title":"Tauroursodeoxycholic acid stimulates hepatocellular exocytosis and mobilizes extracellular Ca++ mechanisms defective in cholestasis","volume":"92","author":"Beuers","year":"1993","journal-title":"Journal of Clinical Investigation"},{"issue":"5","key":"10.1002\/14651858.CD003626.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1053\/gast.1996.v110.pm8613063","article-title":"Tauroursodeoxycholic acid activates protein kinase C in isolated rat hepatocytes","volume":"110","author":"Beuers","year":"1996","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD003626.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1053\/jhep.2001.24034","article-title":"Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver","volume":"33","author":"Beuers","year":"2001","journal-title":"Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD003626.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s12016-008-8085-y","article-title":"Medical treatment of primary sclerosing cholangitis: a role for novel bile acids and other (post-) transcriptional modulators?","volume":"36","author":"Beuers","year":"2009","journal-title":"Clinical Reviews in Allergy and Immunology"},{"issue":"1","key":"10.1002\/14651858.CD003626.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/ije\/dyn188","article-title":"Apparently conclusive meta-analysis may be inconclusive - Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analysis","volume":"38","author":"Brok","year":"2009","journal-title":"International Journal of Epidemiology"},{"issue":"5","key":"10.1002\/14651858.CD003626.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1111\/j.1572-0241.2003.07401.x","article-title":"Is there a role for liver biopsy in primary sclerosing cholangitis?","volume":"98","author":"Burak","year":"2003","journal-title":"American Journal of Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD003626.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/hep.1840110104","article-title":"Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid","volume":"11","author":"Calmus","year":"1990","journal-title":"Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD003626.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.jhep.2008.02.017","article-title":"Incidence and mortality of primary sclerosing cholangitis in the UK: a population-based cohort study","volume":"48","author":"Card","year":"2008","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD003626.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/BF01887799","article-title":"Sclerosing cholangitis: broad spectrum of radiographic features","volume":"9","author":"Chen","year":"1984","journal-title":"Gastrointestinal Radiolology"},{"issue":"4","key":"10.1002\/14651858.CD003626.pub2-BIB0038|cit38","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003181.pub2","article-title":"Bile acids for viral hepatitis","author":"Chen","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD003626.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/BF02213140","article-title":"Tauroursodeoxycholic acid for treatment of primary biliary cirrhosis. A dose-response study","volume":"41","author":"Crosignani","year":"1996","journal-title":"Digestive Diseases and Sciences"},{"issue":"8","key":"10.1002\/14651858.CD003626.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/j.1365-2036.2005.02407.x","article-title":"Review article: current management of primary sclerosing cholangitis","volume":"21","author":"Cullen","year":"2005","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD003626.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/sim.4780060325","article-title":"Methods for combining randomized clinical trials: strengths and limitations","volume":"6","author":"Demets","year":"1987","journal-title":"Statistics in Medicine"},{"issue":"3","key":"10.1002\/14651858.CD003626.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"issue":"1","key":"10.1002\/14651858.CD003626.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/hep.1840130119","article-title":"Dual association of HLA DR2 and DR3 with primary sclerosing cholangitis","volume":"13","author":"Donaldson","year":"1991","journal-title":"Hepatology"},{"issue":"7109","key":"10.1002\/14651858.CD003626.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD003626.pub2-BIB0045|cit45","first-page":"322","article-title":"Alcoholic hepatitis: no glucocorticosteroids?","volume-title":"Steatohepatitis (NASH and ASH). Falk Symposium 121","author":"Gluud","year":"2001"},{"issue":"4","key":"10.1002\/14651858.CD003626.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jhep.2007.01.003","article-title":"Hepatology may have problems with putative surrogate outcome measures","volume":"46","author":"Gluud","year":"2007","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD003626.pub2-BIB0047|cit47","unstructured":"Gluud C Nikolova D Klingenberg SL Alexakis N Als-Nielsen B Colli A Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2010, Issue 9. Art. No.: LIVER"},{"issue":"3","key":"10.1002\/14651858.CD003626.pub2-BIB0048|cit48","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000551.pub2","article-title":"Ursodeoxycholic acid for primary biliary cirrhosis","author":"Gong","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD003626.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.suc.2008.07.010","article-title":"Primary sclerosing cholangitis","volume":"88","author":"Gordon","year":"2008","journal-title":"Surgical Clinics of North America"},{"issue":"4","key":"10.1002\/14651858.CD003626.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1053\/jhep.2002.32931","article-title":"Ursodeoxycholic acid cytoprotection: dancing with death receptors and survival pathways","volume":"35","author":"Guicciardi","year":"2002","journal-title":"Hepatology"},{"issue":"11","key":"10.1002\/14651858.CD003626.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD003626.pub2-BIB0052|cit52","doi-asserted-by":"crossref","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009] The Cochrane Colloboration, 2009. Available from www.cochrane-handbook.org","DOI":"10.1002\/9780470712184"},{"key":"10.1002\/14651858.CD003626.pub2-BIB0053|cit53","volume-title":"International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice1997 CFR & ICH Guidelines","volume":"1","author":"International Conference on Harmonisation Expert Working Group","year":"1997"},{"issue":"2","key":"10.1002\/14651858.CD003626.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/toxsci\/65.2.166","article-title":"Mechanisms of hepatotoxicity","volume":"65","author":"Jaeschke","year":"2002","journal-title":"Toxicological Sciences"},{"issue":"5","key":"10.1002\/14651858.CD003626.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1111\/j.1572-0241.2007.01103.x","article-title":"The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis","volume":"102","author":"Kaplan","year":"2007","journal-title":"American Journal of Gastroenterology"},{"issue":"7","key":"10.1002\/14651858.CD003626.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S0025-6196(11)64614-4","article-title":"A revised natural history model for primary sclerosing cholangitis","volume":"75","author":"Kim","year":"2000","journal-title":"Mayo Clinic Proceedings"},{"issue":"11","key":"10.1002\/14651858.CD003626.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"982","DOI":"10.7326\/0003-4819-135-11-200112040-00010","article-title":"Reported methodological quality and discrepancies between large and small randomized trials in meta-analyses","volume":"135","author":"Kjaergard","year":"2001","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD003626.pub2-BIB0058|cit58","first-page":"1121","article-title":"Sclerosing cholangitis","volume-title":"Oxford Textbook of Clinical Hepatology","volume":"II","author":"LaRusso","year":"1999"},{"issue":"14","key":"10.1002\/14651858.CD003626.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJM199504063321406","article-title":"Primary sclerosing cholangitis","volume":"332","author":"Lee","year":"1995","journal-title":"New England Journal of Medicine"},{"issue":"38","key":"10.1002\/14651858.CD003626.pub2-BIB0060|cit60","first-page":"387","article-title":"Endoscopic therapy in primary sclerosing cholangitis: outcome of treatment and risk of cancer","volume":"48","author":"Linder","year":"2001","journal-title":"Hepatogastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD003626.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1055\/s-2008-1040588","article-title":"Recent advances in the management of primary sclerosing cholangitis","volume":"7","author":"Lindor","year":"1987","journal-title":"Seminars in Liver Disease"},{"issue":"6","key":"10.1002\/14651858.CD003626.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/hep.1840010612","article-title":"Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis","volume":"1","author":"Ludwig","year":"1981","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD003626.pub2-BIB0063|cit63","first-page":"193","article-title":"Primary sclerosing cholangitis","volume-title":"Liver Pathology-Contemporary Issues in Surgical Pathology","author":"Ludwig","year":"1986"},{"issue":"1","key":"10.1002\/14651858.CD003626.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1055\/s-2008-1040417","article-title":"Small-duct primary sclerosing cholangitis","volume":"11","author":"Ludwig","year":"1991","journal-title":"Seminars in Liver Disease"},{"issue":"3","key":"10.1002\/14651858.CD003626.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1055\/s-2007-966253","article-title":"The roles of magnetic resonance and endoscopic retrograde cholangiopancreatography (MRCP and ERCP) in the diagnosis of patients with suspected sclerosing cholangitis: a cost-effectiveness analysis","volume":"39","author":"Meagher","year":"2007","journal-title":"Endoscopy"},{"issue":"10","key":"10.1002\/14651858.CD003626.pub2-BIB0066|cit66","first-page":"242","article-title":"Endoscopic and surgical management of primary sclerosing cholangitis","volume":"10","author":"Michaels","year":"2008","journal-title":"Medscape Journal of Medicine"},{"issue":"9128","key":"10.1002\/14651858.CD003626.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0140-6736(98)01085-X","article-title":"Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses","volume":"352","author":"Moher","year":"1998","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD003626.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/0016-5085(95)90463-8","article-title":"HLA-DR and HLA-DQ are not markers for rapid disease progression in primary sclerosing cholangitis","volume":"108","author":"Olerup","year":"1995","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD003626.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1001\/archinte.1972.03650040130012","article-title":"Bile acids, liver injury and liver disease","volume":"130","author":"Palmer","year":"1972","journal-title":"Archives of Internal Medicine"},{"issue":"3","key":"10.1002\/14651858.CD003626.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1053\/jhep.2002.36088","article-title":"Ursodeoxycholiic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited","volume":"36","author":"Paumgartner","year":"2002","journal-title":"Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD003626.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1089-3261(03)00135-1","article-title":"Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease","volume":"8","author":"Paumgartner","year":"2004","journal-title":"Clinics in Liver Disease"},{"issue":"14","key":"10.1002\/14651858.CD003626.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.3748\/wjg.15.1677","article-title":"Bile-acid-induced cell injury and protection","volume":"15","author":"Perez","year":"2009","journal-title":"World Journal of Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD003626.pub2-BIB0073|cit73","first-page":"I","article-title":"Tauroursodeoxycholic acid for the treatment of chronic hepatitis: a dose-response study (IASL Abstract)","volume":"23","author":"Podda","year":"1996","journal-title":"Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD003626.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1053\/jhep.2002.32533","article-title":"Inhibition of the MAPK and PI3K pathways enhances UDCA-induced apoptosis in primary rodent hepatocytes","volume":"35","author":"Qiao","year":"2002","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD003626.pub2-BIB0075|cit75","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2008"},{"issue":"4","key":"10.1002\/14651858.CD003626.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1017\/S0266462303000552","article-title":"Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches","volume":"19","author":"Royle","year":"2003","journal-title":"International Journal of Technology Assessment in Health Care"},{"issue":"5","key":"10.1002\/14651858.CD003626.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"issue":"9","key":"10.1002\/14651858.CD003626.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/j.1872-034X.2009.00527.x","article-title":"Ursodeoxycholic acid in primary sclerosing cholangitis: meta-analysis of randomized controlled trials","volume":"39","author":"Shi","year":"2009","journal-title":"Hepatology Research"},{"issue":"4","key":"10.1002\/14651858.CD003626.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.1840040416","article-title":"Influence of hydroxylation and conjugation of bile salts on their membrane damaging properties","volume":"4","author":"Sholmerich","year":"1984","journal-title":"Hepatology"},{"issue":"8","key":"10.1002\/14651858.CD003626.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1155\/2008\/824168","article-title":"Primary sclerosing cholangitis","volume":"22","author":"Silveira","year":"2008","journal-title":"Canadian Journal of Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD003626.pub2-BIB0081|cit81","first-page":"178","article-title":"Ursodeoxycholic acid in the treatment of primary sclerosing cholangitis","volume":"28","author":"Stiehl","year":"1996","journal-title":"The Italian Journal of Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD003626.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/S0168-8278(97)80421-7","article-title":"Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis. An 8-year prospective study","volume":"26","author":"Stiehl","year":"1997","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD003626.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/hep.20287","article-title":"Cost-minimization analysis of MRC versus ERCP for the diagnosis of primary sclerosing cholangitis","volume":"40","author":"Talwalkar","year":"2004","journal-title":"Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD003626.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/00054725-200501000-00009","article-title":"Primary sclerosing cholangitis","volume":"11","author":"Talwalkar","year":"2005","journal-title":"Inflammatory Bowel Diseases"},{"issue":"1","key":"10.1002\/14651858.CD003626.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/ije\/dyn179","article-title":"Can trial sequential monitoring boundaries reduce spurious inferences from meta-analysis?","volume":"38","author":"Thorlund","year":"2009","journal-title":"International Journal of Epidemiology"},{"issue":"6","key":"10.1002\/14651858.CD003626.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1002\/lt.21456","article-title":"Current diagnosis and management of primary sclerosing cholangitis","volume":"14","author":"Tischendorf","year":"2008","journal-title":"Liver Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD003626.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/gast.1996.v111.pm8698195","article-title":"Effects of Ursodeoxycholate and cholate feeding on liver disease in FVB mice with a disrupted mdr2 P-glycoprotein gene","volume":"111","author":"Nieuwkerk","year":"1996","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD003626.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"581","DOI":"10.7326\/0003-4819-102-5-581","article-title":"Pericholangitis in chronic ulcerative colitis: primary sclerosing cholangitis of the small bile ducts?","volume":"102","author":"Wee","year":"1985","journal-title":"Annals of Internal Medicine"},{"issue":"7","key":"10.1002\/14651858.CD003626.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0046-8177(85)80158-1","article-title":"Hepatobiliary carcinoma associated with primary sclerosing cholangitis and chronic ulcerative colitis","volume":"16","author":"Wee","year":"1985","journal-title":"Human Pathology"},{"issue":"1","key":"10.1002\/14651858.CD003626.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jclinepi.2007.03.013","article-title":"Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis","volume":"61","author":"Wetterslev","year":"2008","journal-title":"Journal of Clinical Epidemiology"},{"issue":"7644","key":"10.1002\/14651858.CD003626.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/bmj.39465.451748.AD","article-title":"Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study","volume":"336","author":"Wood","year":"2008","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"1-3","key":"10.1002\/14651858.CD003626.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0192-0561(98)00006-X","article-title":"Intragastric administration of ursodeoxycholic acid suppresses immunoglobulin secretion by lymphocytes from liver, but not from peripheral blood, spleen and Peyer's patches in mice","volume":"20","author":"Yoshikawa","year":"1998","journal-title":"International Journal of Immunopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD003626.pub2-BIB0093|cit93","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003626","article-title":"Bile acids for primary sclerosing cholangitis","author":"Chen","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD003626.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T21:49:07Z","timestamp":1758059347000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD003626.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Hepato-Biliary Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2011,1,19]]},"references-count":93,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2011,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd003626.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,19]]}}}